The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates the toxicity and biological activity of dioxins and related chemicals. The AhR influences a variety of processes involved in cellular growth and differentiation, and recent studies have suggested that the AhR is a potential target for immune-mediated diseases. METHODOLOGY/PRINCIPAL FINDINGS: During a screen for molecules that activate the AhR, leflunomide, an immunomodulatory drug presently used in the clinic for the treatment of rheumatoid arthritis, was identified as an AhR agonist. We aimed to determine whether any biological activity of leflunomide could be attributed to a previously unappreciated interaction with the AhR. The currently established mechanism of action of leflunomide involves its metabolism to A771726, possibly by cytochrome P450 enzymes, followed by inhibition of de novo pyrimidine biosynthesis by A771726. Our results demonstrate that leflunomide, but not its metabolite A771726, caused nuclear translocation of AhR into the nucleus and increased expression of AhR-responsive reporter genes and endogenous AhR target genes in an AhR-dependent manner. In silico Molecular Docking studies employing AhR ligand binding domain revealed favorable binding energy for leflunomide, but not for A771726. Further, leflunomide, but not A771726, inhibited in vivo epimorphic regeneration in a zebrafish model of tissue regeneration in an AhR-dependent manner. However, suppression of lymphocyte proliferation by leflunomide or A771726 was not dependent on AhR. CONCLUSIONS: These data reveal that leflunomide, an anti-inflammatory drug, is an agonist of the AhR. Our findings link AhR activation by leflunomide to inhibition of fin regeneration in zebrafish. Identification of alternative AhR agonists is a critical step in evaluating the AhR as a therapeutic target for the treatment of immune disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Activation of the AhR target genes by leflunomide. Hepa1 and HepG2 cells were treated with vehicle (V, 0.1% DMSO), TCDD (T, 1 nM), or leflunomide (L20, 20 µM; L10, 10 µM; L1, 1 µM) for 18 hours. RNA was isolated and semi quantitative RT-PCR was performed for the AhR target genes Cytochrome P450 1A1 (CYP1A1), Cytochrome P450 1A2 (CYP1A2), UDP glucuronosyltransferase 1A1 (UGT1A1), and NAD(P)H dehydrogenase [quinone 1] (NQO1), as described in the methods section. Expression analysis of GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) was performed as a control. Cycle numbers during which PCR reactions were sampled are indicated. PCR products were visualized on a 2% TAE agarose gel stained with ethidium bromide. Leflunomide activated the selected panel of AhR target genes in WT Hepa1 (A) and HepG2 cells (B).](https://figures.cochat.ai/paper-figures/7fff5724e87340e987d1582b6e09519e/the-anti-inflammatory-drug-leflunomide-is-an-agonist-of-the-aryl-hydrocarbon-figure-2.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the binding modes of TCDD and other ligands within the AHR LBD of a given species (typically that of mouse or human AHR) have been predicted by these approaches, experimental confirmation of these proposed interactions are generally lacking.”
From Comparative Analysis of Homology Models of the Ah Receptor Ligand Binding Domain: Verification of Structure–Function Predictions by Site-Directed Mutagenesis of a Nonfunctional Receptor (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More recently, these models have been used in molecular docking studies in an attempt to elucidate the detailed interactions of some known ligands (agonists) within the AHR LBD as well as in the virtual screening of collections of putative ligands (12,18-20,22-25).”
From Comparative Analysis of Homology Models of the Ah Receptor Ligand Binding Domain: Verification of Structure–Function Predictions by Site-Directed Mutagenesis of a Nonfunctional Receptor (2013) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
Determination of lymphocyte division by flow cytometry
Lyons, A. B., & Parish, C. R. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90236-4 · Cited by 1,657
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J.-C., & Stockinger, B. (2008) · Nature · doi:10.1038/nature06881 · Cited by 1,634
The PAS Superfamily: Sensors of Environmental and Developmental Signals
Gu, Y.-Z., Hogenesch, J. B., & Bradfield, C. A. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.519 · Cited by 1,029
Cloning of a Factor Required for Activity of the Ah (Dioxin) Receptor
Hoffman, E. C., Reyes, H., Chu, F.-F., Sander, F., Conley, L. H., Brooks, B. A., & Hankinson, O. (1991) · Science · doi:10.1126/science.1852076 · Cited by 957
The Aryl Hydrocarbon Receptor Complex and the Control of Gene Expression
Beischlag, T. V., Morales, J. L., Hollingshead, B. D., & Perdew, G. H. (2008) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v18.i3.20 · Cited by 727 · cited 16×
“Inhibition of CYP1A2 increases leflunomide-induced AhR reporter gene activity As shown in Figure 4, cytochrome P450-mediated isoxazole ring scission leading to the conversion of leflunomide to A771726 results in a loss of ability to activate the AhR.”
BackgroundInfluentialConversion of Bcl-2 from Protector to Killer by Interaction with Nuclear Orphan Receptor Nur77/TR3
Lin, B., Kolluri, S. K., Lin, F., Liu, W., Han, Y.-H., Cao, X., Dawson, M. I., Reed, J. C., & Zhang, X.-K. (2004) · Cell · doi:10.1016/s0092-8674(04)00162-x · Cited by 671
Self-citationCytochrome c Release and Apoptosis Induced by Mitochondrial Targeting of Nuclear Orphan Receptor TR3
Li, H., Kolluri, S. K., Gu, J., Dawson, M. I., Cao, X., Hobbs, P. D., Lin, B., Chen, G.-Q., Lu, J.-S., Lin, F., et al. (2000) · Science · doi:10.1126/science.289.5482.1159 · Cited by 667
Self-citationThe aryl hydrocarbon receptor: a perspective on potential roles in the immune system
Stevens, E. A., Mezrich, J. D., & Bradfield, C. A. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03054.x · Cited by 413
Cited by
Aryl hydrocarbon receptor ligands in cancer: friend and foe
Murray, I. A., Patterson, A. D., & Perdew, G. H. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3846 · Cited by 883
Sykes, D. B., Kfoury, Y. S., Mercier, F. E., Wawer, M. J., Law, J. M., Haynes, M. K., Lewis, T. A., Schajnovitz, A., Jain, E., Lee, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.057 · Cited by 500
Christian, S., Merz, C., Evans, L., Gradl, S., Seidel, H., Friberg, A., Eheim, A., Lejeune, P., Brzezinka, K., Zimmermann, K., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0461-5 · Cited by 241
Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target
Kolluri, S. K., Jin, U.-H., & Safe, S. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-1981-2 · Cited by 173
“The antiestrogen raloxifene induced apoptosis in TNBC cells, indicating that this compound or its analogs also have potential as AhR-targeted therapeutics for breast cancer therapy (O’Donnell et al. 2014).”
InfluentialSelf-citationSoshilov, A. A., & Denison, M. S. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01183-13 · Cited by 128
“4A) is an atypical AhR agonist recently shown to be an activator of zebrafish AhR1a (an AhR which does not bind TCDD) in vivo (45, 46).”
BackgroundThe Aryl Hydrocarbon Receptor: A Key Bridging Molecule of External and Internal Chemical Signals
Tian, J., Yu, F., Fu, H., Xie, H. Q., Jiang, J. X., & Zhao, B. (2015) · Environmental Science & Technology · doi:10.1021/acs.est.5b00385 · Cited by 128
Drug target prediction through deep learning functional representation of gene signatures
Chen, H., King, F. J., Zhou, B., Wang, Y., Canedy, C. J., Hayashi, J., Zhong, Y., Chang, M. W., Pache, L., Wong, J. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46089-y · Cited by 119
IL-22, cell regeneration and autoimmunity
Nikoopour, E., Bellemore, S. M., & Singh, B. (2014) · Cytokine · doi:10.1016/j.cyto.2014.09.007 · Cited by 112
O'Donnell, E. F., Koch, D. C., Bisson, W. H., Jang, H. S., & Kolluri, S. K. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.549 · Cited by 102
Self-citationJin, U.-H., Lee, S., & Safe, S. H. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.195339 · Cited by 100
AhR and Cancer: From Gene Profiling to Targeted Therapy
Paris, A., Tardif, N., Galibert, M., & Corre, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020752 · Cited by 91
AHR2 Mutant Reveals Functional Diversity of Aryl Hydrocarbon Receptors in Zebrafish
Goodale, B. C., La Du, J. K., Bisson, W. H., Janszen, D. B., Waters, K. M., & Tanguay, R. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029346 · Cited by 89
Self-citationThe Aryl Hydrocarbon Receptor Mediates Leflunomide-Induced Growth Inhibition of Melanoma Cells
O’Donnell, E. F., Kopparapu, P., Koch, D. C., Jang, H. S., Phillips, J. L., Tanguay, R. L., Kerkvliet, N. I., & Kolluri, S. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040926 · Cited by 86
Self-citationWnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype
Sinnberg, T. W., Levesque, M. P., Krochmann, J., Cheng, P. F., Ikenberg, K., Meraz-Torres, F., Niessner, H., Garbe, C., & Busch, C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0773-5 · Cited by 85
Noakes, R. (2015) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s19985 · Cited by 76
Leflunomide: A promising drug with good antitumor potential
Zhang, C., & Chu, M. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.107 · Cited by 77
Zewail, M., Gaafar, P. M. E., Ali, M. M., & Abbas, H. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2079770 · Cited by 75
The aryl hydrocarbon receptor (AhR) as a breast cancer drug target
Baker, J. R., Sakoff, J. A., & McCluskey, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21645 · Cited by 73
Aly, L., Hemmer, B., & Korn, T. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666161208151525 · Cited by 71
Aryl hydrocarbon receptor and experimental autoimmune arthritis
Nguyen, N. T., Nakahama, T., & Kishimoto, T. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0392-6 · Cited by 69
New insights into the aryl hydrocarbon receptor as a modulator of host responses to infection
Lawrence, B. P., & Vorderstrasse, B. A. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0395-3 · Cited by 68
Topical delivery of nanoemulsions for skin cancer treatment
Duarte, J. G., Sharma, A., Sharifi, E., Damiri, F., Berrada, M., Khan, M. A., Singh, S. K., Dua, K., Veiga, F., Mascarenhas‐Melo, F., et al. (2023) · Applied Materials Today · doi:10.1016/j.apmt.2023.102001 · Cited by 68
Fraccalvieri, D., Soshilov, A. A., Karchner, S. I., Franks, D. G., Pandini, A., Bonati, L., Hahn, M. E., & Denison, M. S. (2013) · Biochemistry · doi:10.1021/bi301457f · Cited by 65
Li, L., Dai, Y., & Xia, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114845 · Cited by 65
A Review of the Functional Roles of the Zebrafish Aryl Hydrocarbon Receptors
Shankar, P., Dasgupta, S., Hahn, M. E., & Tanguay, R. L. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa143 · Cited by 63
Self-citationZhang, L., Zhang, J., Wang, J., Ren, C., Tang, P., Ouyang, L., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114176 · Cited by 63
Oncology Therapeutics Targeting the Metabolism of Amino Acids
Muhammad, N., Lee, H. M., & Kim, J. (2020) · Cells · doi:10.3390/cells9081904 · Cited by 62
Liang, C., Li, J., Lu, C. C., Xie, D., Liu, J., Zhong, C., Wu, X., Dai, R., Zhang, H., Guan, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12163-z · Cited by 61
Alamri, R. D., Elmeligy, M. A., Albalawi, G. A., Alquayr, S. M. A., Alsubhi, S. S., & El-Ghaiesh, S. H. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107398 · Cited by 61
Amino Acid Metabolism in Rheumatoid Arthritis: Friend or Foe?
Panfili, E., Gerli, R., Grohmann, U., & Pallotta, M. T. (2020) · Biomolecules · doi:10.3390/biom10091280 · Cited by 60
Punj, S., Kopparapu, P., Jang, H. S., Phillips, J. L., Pennington, J. M., Rohlman, D., O’Donnell, E. F., Iversen, P. L., Kolluri, S. K., & Kerkvliet, N. I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088726 · Cited by 60
Self-citationThe emerging role of aryl hydrocarbon receptor in the activation and differentiation of Th17 cells
Baricza, E., Tamási, V., Marton, N., Buzás, E. I., & Nagy, G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2056-2 · Cited by 58
A redox-mediated Kemp eliminase
Li, A., Wang, B., Ilie, A., Dubey, K. D., Bange, G., Korendovych, I. V., Shaik, S. S., & Reetz, M. T. (2017) · Nature Communications · doi:10.1038/ncomms14876 · Cited by 55
Perkins, A., Phillips, J., Kerkvliet, N., Tanguay, R., Perdew, G., Kolluri, S., & Bisson, W. (2014) · Biology · doi:10.3390/biology3040645 · Cited by 52
Self-citationDolciami, D., Ballarotto, M., Gargaro, M., Lopez-Cara, L. C., Fallarino, F., & Macchiarulo, A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111842 · Cited by 52
Koch, D. C., Jang, H. S., O’Donnell, E. F., Punj, S., Kopparapu, P., Bisson, W. H., Kerkvliet, N. I., & Kolluri, S. K. (2015) · Oncogene · doi:10.1038/onc.2015.55 · Cited by 52
Self-citationCell-specific transcriptional control of mitochondrial metabolism by TIF1γ drives erythropoiesis
Rossmann, M. P., Hoi, K. K., Chan, V., Abraham, B. J., Yang, S. P., Mullahoo, J., Papanastasiou, M., Wang, Y., Elia, I., Perlin, J. R., et al. (2021) · Science · doi:10.1126/science.aaz2740 · Cited by 50
Bock, K. W. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0303 · Cited by 44
Elson, D. J., & Kolluri, S. K. (2023) · Biology · doi:10.3390/biology12040526 · Cited by 44
Self-citationHe, T., Haapa-Paananen, S. M., Kaminskyy, V. O., Kohonen, P. J., Fey, V., Zhivotovsky, B., Kallioniemi, O., & Perälä, M. (2013) · Oncogene · doi:10.1038/onc.2013.313 · Cited by 41
Souder, J. P., & Gorelick, D. A. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz075 · Cited by 41
The AhR Signaling Mechanism: A Structural Point of View
Bonati, L., Motta, S., & Callea, L. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168296 · Cited by 37
Deciphering the roles of aryl hydrocarbon receptor (AHR) in regulating carcinogenesis
Chong, Z. X., Yong, C. Y., Ong, H. K., Yeap, S. K., & Ho, W. Y. (2023) · Toxicology · doi:10.1016/j.tox.2023.153596 · Cited by 37
Epigenetic Regulations of AhR in the Aspect of Immunomodulation
Wajda, A., Łapczuk-Romańska, J., & Paradowska‐Gorycka, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176404 · Cited by 34
Shan, A., Leng, L., Li, J., Luo, X.-M., Fan, Y.-J., Yang, Q., Xie, Q., Chen, Y., Ni, C., Guo, L.-M., et al. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.122869 · Cited by 32
Baban, B., Liu, J. Y., & Mozaffari, M. S. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00315.2012 · Cited by 32
Muehler, A. R., Kohlhof, H., Groeppel, M., & Vitt, D. (2019) · Drugs in R&D · doi:10.1007/s40268-019-00286-z · Cited by 31
A data-driven methodology towards evaluating the potential of drug repurposing hypotheses
Santamaría, L. P., Carro, E. U., Uzquiano, M. D., Menasalvas, E., Gallardo, Y. P., & Rodríguez‐González, A. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.003 · Cited by 29
Suppression of glioblastoma by a drug cocktail reprogramming tumor cells into neuronal like cells
Gao, L., Huang, S., Zhang, H., Hua, W., Xin, S., Cheng, L., Guan, W., Yu, Y., Mao, Y. Q., & Pei, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-39852-5 · Cited by 30
Omeprazole Inhibits Glioblastoma Cell Invasion and Tumor Growth
Jin, U.-H., Michelhaugh, S. K., Polin, L., Shrestha, R., Mittal, S., & Safe, S. H. (2020) · Cancers · doi:10.3390/cancers12082097 · Cited by 29
Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway
Genthe, J. R., Min, J., Farmer, D. M., Shelat, A. A., Grenet, J. A., Lin, W., Finkelstein, D., Vrijens, K., Chen, T., Guy, R. K., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00527 · Cited by 29
Fakan, B., Szalárdy, L., & Vécsei, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020426 · Cited by 28
Wu, J., Pang, T., Lin, Z., Zhao, M., & Jin, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965941 · Cited by 28
Wang, W., Zhou, H., & Liu, L. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153136 · Cited by 28
van den Brink, N. J. M., Pardow, F., Meesters, L. D., van Vlijmen‐Willems, I. M. J. J., Rodijk‐Olthuis, D., Niehues, H., Jansen, P. A. M., Roelofs, S. H., Brewer, M. G., van den Bogaard, E. H. J., et al. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.03.038 · Cited by 28
Bonati, L., Corrada, D., Giani Tagliabue, S., & Motta, S. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.01.011 · Cited by 27
Lung regeneration after toxic injury is improved in absence of dioxin receptor
Morales‐Hernández, A., Nacarino-Palma, A., Moreno-Marín, N., Barrasa, E., Paniagua, B., Catalina‐Fernández, I., Alvarez, A. M., Bustelo, X. R., Merino, J. M., & Fernández‐Salguero, P. M. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.10.009 · Cited by 25
Leflunomide suppresses growth in human medullary thyroid cancer cells
Alhefdhi, A., Burke, J. F., Redlich, A., Kunnimalaiyaan, M., & Chen, H. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.05.089 · Cited by 25
O’Donnell, E. F., Jang, H. S., Liefwalker, D. F., Kerkvliet, N. I., & Kolluri, S. K. (2021) · APOPTOSIS · doi:10.1007/s10495-021-01666-0 · Cited by 25
Self-citationAccess Path to the Ligand Binding Pocket May Play a Role in Xenobiotics Selection by AhR
Szöllősi, D., Erdei, Á., Gyimesi, G., Magyar, C., & Hegedűs, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146066 · Cited by 24
Huang, C.-F., Lin, Y., Chiang, Z.-C., Lu, S.-Y., Kuo, Y., Chang, S. L., & Chao, P. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2014.01.005 · Cited by 24
Choudhary, M., Safe, S. H., & Malek, G. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.02.015 · Cited by 23
Predictive modeling of aryl hydrocarbon receptor (AhR) agonism
Goya‐Jorge, E., Giner, R. M., Veitía, M. S., Gozalbes, R., & Barigye, S. J. (2020) · Chemosphere · doi:10.1016/j.chemosphere.2020.127068 · Cited by 22
Ma, L., Wu, Z., Wang, L., Zhang, X., Wang, J., Chen, C., Ni, X., Lin, Y., Cao, Y., Luan, Y., et al. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.157 · Cited by 22
Leflunomide: dermatologic perspective
Sehgal, V. N., & Verma, P. (2011) · Journal of Dermatological Treatment · doi:10.3109/09546634.2011.595383 · Cited by 22
Mehta, V., & Vezina, C. M. (2011) · Differentiation · doi:10.1016/j.diff.2011.05.011 · Cited by 21
Tarachand, S. P., Thirumoorthy, G., Lakshmaiah, V. V., & Nagella, P. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2037463 · Cited by 21
Targeting the aryl hydrocarbon receptor with a novel set of triarylmethanes
Goya‐Jorge, E., Rampal, C., Loones, N., Barigye, S. J., Carpio, L. E., Gozalbes, R., Ferroud, C., Veitía, M. S., & Giner, R. M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112777 · Cited by 20
Mencarelli, A., Francisci, D., Renga, B., D’Amore, C., Cipriani, S., Basile, F., Schiaroli, E., Baldelli, F., & Fiorucci, S. (2012) · Antiviral Therapy · doi:10.3851/imp2039 · Cited by 20
Hayek, S., Pietrancosta, N., Hovhannisyan, A. A., de Sousa, R. A., Bekaddour, N., Ermellino, L., Tramontano, E., Arnould, S., Sardet, C., Dairou, J., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111855 · Cited by 20
O’Donnell, E. F., Jang, H. S., Pearce, M. C., Kerkvliet, N. I., & Kolluri, S. K. (2017) · Oncotarget · doi:10.18632/oncotarget.16056 · Cited by 20
Self-citationIdentification of a Raloxifene Analog That Promotes AhR-Mediated Apoptosis in Cancer Cells
Jang, H. S., Pearce, M. C., O’Donnell, E. F., Nguyen, B., Truong, L., Mueller, M., Bisson, W. H., Kerkvliet, N. I., Tanguay, R. L., & Kolluri, S. K. (2017) · Biology · doi:10.3390/biology6040041 · Cited by 20
Self-citationEl‐Ghiaty, M. A., Alqahtani, M. A., & El‐Kadi, A. O. S. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110049 · Cited by 18
Islam, A. B. M. M. K., Dave, M. N., Amin, S., Jensen, R. V., & Amin, A. R. (2016) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2014.09.005 · Cited by 17
Loss of the aryl hydrocarbon receptor increases tumorigenesis in p53-deficient mice
Phillips, J. L., Löhr, C. V., Nguyen, B. D., Buermeyer, A. B., & Kolluri, S. K. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116191 · Cited by 17
Self-citationCancer and Autoimmune Diseases as Two Sides of Chronic Inflammation and the Method of Therapy
Rogovskii, V. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096282480240105071638 · Cited by 17
Zhang, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065128 · Cited by 16
Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML
DeRatt, L. G., Zhang, Z., Pietsch, C., Cisar, J. S., Zhang, X., Wang, W., Tanner, A., Matico, R., Shaffer, P. L., Jacoby, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00809 · Cited by 15
Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review
Tian, X., Zheng, S., Wang, J., Yu, M., Lin, Z., Qin, M., Wu, Y., Chen, S., & Zhong, S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2078301 · Cited by 15
Nguyen, B. D., Stevens, B. L., Elson, D. J., Finlay, D., Gamble, J. T., Kopparapu, P., Tanguay, R. L., Buermeyer, A. B., Kerkvliet, N. I., & Kolluri, S. K. (2022) · FEBS Journal · doi:10.1111/febs.16683 · Cited by 14
Self-citationElson, D. J., Nguyen, B. D., Bernales, S., Chakravarty, S., Jang, H. S., Korjeff, N. A., Zhang, Y., Wilferd, S. F., Castro, D. J., Plaisier, C. L., et al. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00253 · Cited by 14
Self-citationAryl Hydrocarbon Receptor as a Therapeutical Target of Environmentally Induced Skin Conditions
Freitas, C. A., da Silva, M. S., Santos, B. A. M. C., & Rodrigues, C. R. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.122.000627 · Cited by 13
Haupt, J., Keminer, O., Neser, C., Windshügel, B., Wiltzsch, V., Schmidt, J. R., Pliushcheuskaya, P., Künze, G., Scholz, U., Müller, C., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117066 · Cited by 13
Elson, D. J., Nguyen, B. D., Wood, R., Zhang, Y., Puig-Sanvicens, V., & Kolluri, S. K. (2022) · FEBS Letters · doi:10.1002/1873-3468.14434 · Cited by 13
Self-citationElson, D. J., Nguyen, B. D., Korjeff, N. A., Wilferd, S. F., Puig-Sanvicens, V., Jang, H. S., Bernales, S., Chakravarty, S., Belmar, S., Ureta, G., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115706 · Cited by 13
Self-citationHasani, M., Sani, N. A., Khodabakhshi, B., Arabi, M. S., Mohammadi, S., & Yazdani, Y. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00293-0 · Cited by 12
Larigot, L., Bui, L. C., de Bouvier, M., Pierre, O., Pinon, G. M., Fiocca, J., Ozeir, M., Tourette, C., Ottolenghi, C., Imbeaud, S., et al. (2022) · Antioxidants · doi:10.3390/antiox11051030 · Cited by 12
Activation of the Ah Receptor Modulates Gastrointestinal Homeostasis and the Intestinal Microbiome
Muku, G. E., Murray, I. A., & Perdew, G. H. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00197-2 · Cited by 12
The Role of Aryl Hydrocarbon Receptor in the Pathogenesis and Treatment of Psoriasis
Lin, X., Meng, X., & Lin, J. (2024) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754241239050 · Cited by 12
Kim, J., Im, I., Kim, H., Jeon, J. S., Kang, E., Jo, S., Chun, H., Yoon, S., Kim, J., Kim, S. K., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201903110r · Cited by 11
CRISPR/Cas9 genetic screens in hepatocellular carcinoma gene discovery
Chiu, C. H. (2023) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2023.100127 · Cited by 10
Gehlot, P., & Vyas, V. K. (2023) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892818666230417094939 · Cited by 10
Toxicity of teriflunomide in aryl hydrocarbon receptor deficient mice
Redaelli, C., Gaffarogullari, E. C., Brune, M., Pilz, A. C., Becker, S., Sonner, J. K., Jäschke, A., Gröne, H., Wick, W., Platten, M., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.111 · Cited by 10
Leflunomide Induces Pulmonary and Hepatic CYP1A Enzymes via Aryl Hydrocarbon Receptor
Patel, A., Zhang, S., Maturu, P., Jiang, W., Wang, L., Moorthy, B., & Shivanna, B. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066084 · Cited by 10
Identification of viable TCDD access pathways to human AhR PAS-B ligand binding domain
Casalegno, M., Raos, G., & Sello, G. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.107886 · Cited by 9
Liu, Y., Wei, Y., Zhang, S., Yan, X., Zhu, H., Xu, S. L., Zhao, B., Xie, H. Q., & Yan, B. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00431 · Cited by 9
Rihel, J., & Ghosh, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-05392-9_135 · Cited by 8
Targeting vulnerability in tumor therapy: Dihydroorotate dehydrogenase
Lin, F., Li, J., Zhou, L., Yi, R., Chen, Y., & He, S. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123612 · Cited by 8
Shrestha, A. K., Menon, R., & Shivanna, B. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.149 · Cited by 8
Zhang, B., Wang, Y., Jia, C., Li, S., Wang, X. W., Xu, Y., Chen, A.-Y., Xu, H.-P., Wang, C., Yang, Z., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108678 · Cited by 7
Metadata
- Authors
- O'Donnell, E. F., Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., & Kolluri, S. K.
- Affiliations
- Oregon State University (US)
- University of Geneva (CH)
- Corresponding author
- Kolluri, Siva Kumar
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-10-01
- Volume
- 5
- Issue
- 10
- Pages
- e13128
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2948512
- OpenAlex
- W2009762618
- Cited by
- 124
- References
- 45
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 6 · 2023: 12 · 2022: 14 · 2021: 7 · 2020: 9 · 2019: 14 · 2018: 7 · 2017: 9 · 2016: 5 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 6
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Science Foundation (0641409)
- U.S. Department of Defense (W81XWH)
- National Institutes of Health (1f31ca144571-01)
- National Cancer Institute (F31 CA144571, 1F31CA144571-01)
- National Institute of Environmental Health Sciences (ES-00-210, R01ES016651, P30ES000210, ES016651, P42ES016465, T32ES007060)
- Topics
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Toxic Organic Pollutants Impact
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- leflunomide, aryl hydrocarbon receptor, AhR agonists, A771726, pyrimidine biosynthesis inhibition, cytochrome P450 metabolism, nuclear translocation, epimorphosis, fin regeneration, zebrafish, lymphocyte proliferation, rheumatoid arthritis, anti-inflammatory agents, immune-mediated diseases
- MeSH terms
- Leflunomide, Animals, Anti-Inflammatory Agents, Base Sequence, Cell Line, Fluorescent Antibody Technique, Isoxazoles, Ligands, Mice, Inbred C57BL, Regeneration, Zebrafish, Polymerase Chain Reaction, Genes, Reporter, DNA Primers, Receptors, Aryl Hydrocarbon, Cytochrome P-450 CYP1A2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.